Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection

Loading...
Thumbnail Image
File version
Version of Record (VoR)
Author(s)
Supramaniam, A
Tayyar, Y
Clarke, DTW
Kelly, G
Acharya, D
Morris, KV
McMillan, NAJ
Idris, A
Primary Supervisor
Other Supervisors
Editor(s)
Date
2023
Size
File type(s)
Location
License
http://creativecommons.org/licenses/by/4.0/
Abstract

RNA interference (RNAi) is an emerging and promising therapy for a wide range of respiratory viral infections. This highly specific suppression can be achieved by the introduction of short-interfering RNA (siRNA) into mammalian systems, resulting in the effective reduction of viral load. Unfortunately, this has been hindered by the lack of a good delivery system, especially via the intranasal (IN) route. Here, we have developed an IN siRNA encapsulated lipid nanoparticle (LNP) in vivo delivery system that is highly efficient at targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and respiratory syncytial virus (RSV) lung infection in vivo. Importantly, IN siRNA delivery without the aid of LNPs abolishes anti-SARS-CoV-2 activity in vivo. Our approach using LNPs as the delivery vehicle overcomes the significant barriers seen with IN delivery of siRNA therapeutics and is a significant advancement in our ability to delivery siRNAs. The study presented here demonstrates an attractive alternate delivery strategy for the prophylactic treatment of both future and emerging respiratory viral diseases.

Journal Title
Journal of Microbiology, Immunology and Infection
Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2023, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Item Access Status
Note
This publication has been entered in Griffith Research Online as an advanced online version.
Access the data
Related item(s)
Subject
Nanomedicine
Biomedical and clinical sciences
Clinical sciences
Immunology
COVID-19
Intranasal
LNP
RSV
SARS-CoV-2
Persistent link to this record
Citation
Supramaniam, A; Tayyar, Y; Clarke, DTW; Kelly, G; Acharya, D; Morris, KV; McMillan, NAJ; Idris, A, Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection, Journal of Microbiology, Immunology and Infection, 2023
Collections